Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Hypertension

Renin-angiotensin system inhibitors not linked to COVID-19 severity, researchers conclude

The study’s findings support current guidelines for the treatment of hypertension during the COVID-19 pandemic.

Open access article

The Royal Pharmaceutical Society has made this article free to access in order to help healthcare professionals stay informed about an issue of national importance.

To learn more about coronavirus, please visit: https://www.rpharms.com/resources/pharmacy-guides/wuhan-novel-coronavirus

Chinese woman having blood pressure taken

Source: Akhararat Wathanasing / Alamy Stock Photo

Researchers found that although patients with hypertension had more severe presentations of COVID-19 than those without, there were no significant differences in disease severity according to ACEI or ARB use

Among people with hypertension, the severity of COVID-19 is not associated with the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), data from Wuhan, China, suggest (23 April 2020)[1].

The study, in JAMA Cardiology, was a case series of 1,178 patients with confirmed COVID-19 treated at a single hospital between 15 January 2020 and 15 March 2020. Overall, 362 (30.7%) patients had hypertension and 115 (31.8%) of these were taking ACEIs or ARBs.

The researchers found that patients with hypertension had more severe presentations of COVID-19 than those without and were more likely to die in hospital (21.3% vs 6.5%). However, in those with hypertension, there were no significant differences in the proportion of patients taking ACEIs or ARBs among those with severe and non-severe infections (32.9% vs 30.7%) or non-survivors and survivors (27.3% vs 33.0%).

The ACE2 receptor is used by the SARS-CoV-2 virus to gain access to cells, the researchers explained, but they said there were no previous data to indicate whether patients taking these drugs were at an increased risk of poor outcomes. Several organisations, including the American Heart Association, do not recommend switching drug treatment class in hypertension because of COVID-19.

“These data support current guidelines and societal recommendations for treating hypertension during the COVID-19 pandemic,” the researchers concluded.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20207969

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.